Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck has announced the top-line results of its Vorapaxar from the TRA-2P (Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events) study.
Subscribe to our email newsletter
Vorapaxar, an investigational oral Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist, is being developed for the prevention of thrombosis, thereby reducing cardiovascular death (CVD).
TRA-2P study demonstrated that the addition of Vorapaxar to standard of care significantly reduced the risk of cardiovascular events, heart attack, stroke or urgent coronary revascularization.
Patients taking Vorapaxar also showed considerable increase in bleeding, including intracranial hemorrhage (ICH).
The findings from the TRA-2P trial will be presented at the American College of Cardiology Scientific Sessions in March 2012.